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Abstract: Triple-negative breast cancer (TNBC) occurs in 10–15% of all breast cancer patients, yet it
accounts for about half of all breast cancer deaths. There is an urgent need to identify new antitumor
targets to provide additional treatment options for patients afflicted with this aggressive disease.
Preclinical evidence suggests a critical role for insulin-like growth factor-2 (IGF2) and androgen
receptor (AR) in regulating TNBC progression. To advance this work, a panel of TNBC cell lines was
investigated with all cell lines showing significant expression of IGF2. Treatment with IGF2 stimulated
cell proliferation in vitro (p < 0.05). Importantly, combination treatments with IGF1R inhibitors
BMS-754807 and NVP-AEW541 elicited significant inhibition of TNBC cell proliferation (p < 0.001).
Based on Annexin-V binding assays, BMS-754807, NVP-AEW541 and enzalutamide induced TNBC
cell death (p < 0.005). Additionally, combination of enzalutamide with BMS-754807 or NVP-AEW541
exerted significant reductions in TNBC proliferation even in cells with low AR expression (p < 0.001).
Notably, NVP-AEW541 and BMS-754807 reduced AR levels in BT549 TNBC cells. These results
provide evidence that IGF2 promotes TNBC cell viability and proliferation, while inhibition of
IGF1R/IR and AR pathways contribute to blockade of TNBC proliferation and promotion of apoptosis
in vitro.
Keywords: triple-negative breast cancer; insulin-like growth factor-2; androgen receptor; BMS-754807;
NVP-AEW541; enzalutamide; IGF1R/IR inhibition; IGF2 signaling; AKT kinase; apoptosis
1. Introduction
Breast cancer (BC) is the second leading cause of cancer death among women [1–3]. Most patients
with BC have tumors that express estrogen receptor-α (ERα-66kD) and/or progesterone receptor (PR) at
diagnosis and therefore are candidates for endocrine treatments to improve clinical outcomes. However,
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triple-negative breast cancers (TNBC) are a heterogeneous subtype of BCs that lack nuclear expression
of estrogen receptor-α (ERα-66kD) and progesterone receptor (PR) and have no overexpression of HER2
receptors [4,5]. Consequently, targeted endocrine and HER2-directed therapies are not recommended
for management of TNBCs. Although TNBCs account for 15–20% of all BC cases [1], TNBCs account for
almost half of all BC deaths [1,4,6,7]. TNBCs are generally larger in size, initially of higher grade, exhibit
lymph node involvement at diagnosis and are biologically more aggressive than other BC subtypes [8].
Women diagnosed with TNBC have shorter overall survival and a higher risk of both local and distant
recurrence, and metastases are more likely to occur in the brain and lungs rather than bone as compared
to other breast cancers [8]. Women diagnosed with TNBC experience higher rates of recurrence [7,9].
Identification of novel therapeutic approaches for TNBC is critical because the median survival for
women with metastatic TNBC is currently less than 12 months, and virtually all women with metastatic
TNBC ultimately die of their disease despite systemic cytotoxic chemotherapy.
The progression of TNBC remains to be fully understood. The identification of novel targets in the
proliferative process in TNBC could ultimately help to improve the outcomes of patients diagnosed
with this deadly disease. Current evidence indicates that insulin/insulin-like growth factor (IGF)
signaling pathways play a significant role in BC progression [10–14]. The circulating regulatory
hormones of this system include insulin, insulin-like growth factor-1 (IGF1) and insulin-like growth
factor-2 (IGF2). These circulating growth hormones are reported to enhance TNBC progression [12,15–17],
and the bioavailability in vivo of both IGF1 and IGF2 are modulated by six different IGF-binding
proteins (IGFBPs) [18–20].
Importantly, IGF2 is highly expressed in archival TNBC samples from women in the clinic [21].
IGF2 binding to IGF1R/IR-A in vitro is reported to facilitate downstream signaling for TNBC
cell survival that is mediated in part by modulating the activity of estrogen receptor-beta (ERβ)
which differs from the classical ERα [12,21]. Normally, circulating IGF2 is bound by mannose-6
phosphate/IGF2 receptor (IGF2R) and IGFBPs, predominantly by IGFBP-6 [20,22]. However, IGF2 also
binds to tumor cell surface IGF1R and IR, with preference for IR isoform A (IR-A). IGF1R and IR are
both receptor tyrosine kinases that are expressed in TNBC cells, with evidence of IGF1R amplification in
some archival TNBC specimens obtained after neoadjuvant treatments in the clinic [23]. The activation
of IGF1R and IR heterodimers stimulates downstream effectors in the mitogen-activated protein kinase
(MAPK) and/or phosphatidylinositol 3-kinase (PI3K) AKT/protein kinase B (PKB) pathways resulting
in tumor progression [19]. Although early phase clinical trials raised hope for the use of IGF1R-specific
antibodies for cancer therapy, results from phase II–III trials of these agents in unselected patients
have not demonstrated significant benefits in the clinic [24]. At this time, further investigations
are focusing on specific signaling pathways that may prove effective in the clinic [24,25]. To date,
limited investigation has focused on pathways stimulated by IGF2 in TNBC progression and the
therapeutic potential of targeting identified pathways to improve patient outcomes. Further clinical
interventions may benefit from discovery of alternative strategies to target this critical pathway and
the identification of predictive biomarkers to select patients as candidates for IGF-targeted therapies.
The androgen receptor (AR), a member of the nuclear steroid hormone receptor superfamily,
is reported to be expressed in most invasive breast cancers when ER and PR are not detectable, as well
as in 17–35% of established TNBC specimens [26–30]. Although the exact role of ARs in TNBC remains
to be elucidated, current research indicates that AR is highly conserved throughout TNBC progression
and impacts tumor proliferation [28,29,31]. Inhibition of AR signaling significantly reduces TNBC cell
proliferation, migration, invasion and increases apoptosis in vitro, while significant reduction of tumor
viability is reported by AR inhibition in vivo [32,33]. TNBCs with high levels of AR expression are
also reported to correlate with poor clinical outcomes [29]. Additionally, independent work shows that
AR overexpression in tamoxifen-resistant breast tumors results in constitutive activation of IGF1R and
PI3K/AKT pathways [34].
Systemic chemotherapy is currently the standard of care for neoadjuvant and/or adjuvant
treatment of patients with TNBC, yet recurrence rates and mortality remain high in women with
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this aggressive disease [9,35]. Apart from early clinical trial data indicating antitumor efficacy of
immune checkpoint inhibitors in a minority of patients with TNBC [36,37], targeted treatment options
for women with TNBC are currently not available. Thus, the identification of biologic targets that block
the progression of TNBCs could lead to reduced recurrence of this deadly disease, thereby leading to
improved patient outcomes. Due to their altered expression and potential dysregulated downstream
signaling pathways in TNBC, assessing interactions of IGF and AR pathways in this disease may help
to better understand the underlying processes of TNBC progression, as well as provide novel targets
to ultimately improve patient survival. To this end, we investigated the antitumor effect of inhibiting
the IGF1R/IR and AR pathways alone and in combination in a panel of established TNBC cell lines.
Results of this preclinical study suggest that inhibition of IGF1R//IR and AR pathways significantly
reduce TNBC progression and stimulate TNBC cell death.
2. Results
2.1. IGF2 Promotes the Viability of TNBC Cells
Although IGF2 is highly expressed in archival TNBC specimens from the clinic [21], direct effects
of IGF2 on TNBC cell proliferation and/or viability remain to be fully elucidated. This clinical
data raises the hypothesis that IGF2 may have the ability, in part, to promote tumor growth via
autocrine and/or paracrine mechanisms. To assess the effect of IGF2 treatment on cell viability and
proliferation, we first exposed TNBC cells to IGF2 (100 ng/mL) using serum-free and phenol red-free
media. In these in vitro studies at 72 h post-treatment, IGF2 significantly promoted cell proliferation in
T47D (ERα+/ERβ+) cells, as well as in TNBC MDA-MB-231 and HCC 1937 cells (Figure 1; p < 0.05),
and the action is significantly different from that in control cells.
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refreshed every 24 h. Viable cells were counted using trypan blue exclusion. Data represents at least 
three independent experiments performed in duplicate. *** p ≤ 0.0002; ** p ≤ 0.007; * p ≤ 0.05. Error bars 
represent standard deviation. T47D (ERα+/PR+ BC cell line) used as a positive control.  
These results suggest that IGF2 may play an important role, in part, in maintaining TNBC 
viability and proliferative activity. 
2.2. IGF2 Treatment Impacts Downstream TNBC Signaling Molecules 
In view of previous reports on the potential relationship between IGF1R and AR signaling 
pathways [19,32,34], we investigated our panel of TNBC cell lines for the presence of IGF1R signaling 
mediators and AR. In each TNBC cell line, IGF2 as well as IGF1R and IR are detected in varying 
amounts (Figure 2A, Lanes 1–6). 
Figure 1. Insulin-like growth factor-2 (IGF2) promotes triple-negative breast cancer (TNBC) cell viability.
Initial plating consisted of 1.0× 105 cells per well. Plated cells were cultured in complete media for 48 h
followed by incubation in serum- and phenol red-free medium for 24 h. Cultures were then maintained
in IGF2 (100 ng/mL)-containing media for 24, 48 and 72 h. IGF2 culture media was refreshed every
24 h. Viable cells were counted using trypan blue exclusion. Data represents at least three independent
experiments performed in duplicate. *** p ≤ 0.0002; ** p ≤ 0.007; * p ≤ 0.05. Error bars represent
standard deviation. T47D (ERα+/PR+ BC cell line) used as a positive control.
These results suggest that IGF2 may play an important role, in part, in maintaining TNBC viability
and proliferative activity.
2.2. IGF2 Treatment Impacts Downstream TNBC Signaling Molecules
In view of previous reports on the potential relationship between IGF1R and AR signaling
pathways [19,32,34], we investigated our panel of TNBC cell lines for the presence of IGF1R signaling
mediators and AR. In each TNBC cell line, IGF2 as well as IGF1R and IR are detected in varying
amounts (Figure 2A, Lanes 1–6).
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As previously reported [32,38,39], AR is readily detected in T47D (ERα+/ERβ+/PR+) and TNBC
BT549 (ER-/PR-/HER-) cells, with minimal levels in MDA-MB-231 (ER-/PR-/HER2-) cells (Figure 2A).
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Figure 6. (A–D) Effects of dual therapy with IGF1R/IR and AR antagonists on TNBC proliferation. 
TNBC cells were grown in 96-well plates to 50–60% confluence in complete media. (A) Cells were 
maintained in phenol red-free RMPI 1640 media supplemented with 2% cFBS and either NVP-
AEW541 (8 μM, IGF1R inhibitor; Selleckchem) or BMS-754807 (20 μM, IGF1R/InsR inhibitor; 
Selleckchem), alone or in combination; (B) Cells were exposed to media containing enzalutamide  
(20 μM, AR inhibitor; Selleckchem) and proliferation was assessed after 72 h; (C) Cells were cultured 
in media containing BMS-754807 and enzalutamide for 72 h or (D) in media containing NVP-AEW754 
and enzalutamide for 72 h. Thereafter, cell proliferation was measured using the Celltiter 96® Aqueous 
Proliferation Assay (Promega, Madison, WI, USA). # p-value < 0.05, * p-value < 0.001. SD: standard 
deviation (n = 3). 
2.4. BMS-754807 and NVP-AEW541 Alter AR Expression in Mesenchyma-Subtype TNBC Cells 
To find if the reduction of TNBC proliferation in response to combined treatments with either 
BMS-754807 or NVP-AEW541 may also affect AR expression (Figure 7), we assessed AR levels in 
BT549 cells that express a robust amount of AR under baseline conditions (Figure 2, Lane 5). 
Figure 5. TNBC cell death is promoted by IGF1R/IR and AR antagonists. Results show % cell death of
vehicle-treated controls. An independent control was used for each cell line. TNBC cells were exposed
to either BMS-754807 (20 µM), NVP-AEW541 (8 µM) or enzalutamide (20 µM) (n = 3 independent
experiments). Error bars represent standard deviation (SD). Data was analyzed by Prism GraphPad
software using an unpaired Student t-test. p-Value < 0.05 are considered significant. ** p ≤ 0.005;
* p ≤ 0.05.
Int. J. Mol. Sci. 2017, 18, 2305 7 of 14 
 
 
Figure 5. TNBC cell death is promoted by IGF1R/IR and AR antagonists. Results show % cell death 
of vehicle-treated controls. An independent control was used for each cell line. TNBC cells were 
exposed to either BMS-754807 (20 μM), NVP-AEW541 (8 μM) or enzalutamide (20 μM) (n = 3 
independent experiments). Error bars represent standard deviation (SD). Data was analyzed by Prism 
Gra hPad software using an unpaired Student t-test. p-Value < 0.05 are considered significant. ** p ≤ 
0.005; * p ≤ 0.05. 
 
Figure 6. (A–D) Effects of dual therapy with IGF1R/IR and AR antagonists on TNBC proliferation. 
TNBC cells were grown in 96-well plates to 50–60% confluence in complete media. (A) Cells were 
maintained in phenol red-free RMPI 1640 media supplemented with 2% cFBS and either NVP-
AEW541 (8 μM, IGF1R inhibitor; Selleckchem) or BMS-754807 (20 μM, IGF1R/InsR inhibitor; 
Selleckchem), alone or in combination; (B) Cells were exposed to media containing enzalutamide  
(20 μM, AR inhibitor; Selleckchem) and proliferation was assessed after 72 h; (C) Cells were cultured 
in media containing BMS-754807 and enzalutamide for 72 h or (D) in media containing NVP-AEW754 
and enzalutamide for 72 h. Thereafter, cell proliferation was measured using the Celltiter 96® queous 
Proliferation Assay (Promega, Madison, WI, USA). # p-value < 0.05, * p-value < 0.001. SD: standard 
deviation (n = 3). 
2.4. BMS-754807 and NVP-AEW541 Alter AR Expression in Mesenchyma-Subtype TNBC Cells 
To find if the reduction of TNBC proliferation in response to combined treatments with either 
BMS-754807 or NVP-AEW541 may also aff ct AR expression (Figure 7), we assess d AR levels in 
T549 cells that express a robust mount of AR under ba eline conditions (Figure 2, Lane 5). 
Figure 6. (A–D) Effects of dual therapy wit 1R/I and AR antagonists on TNBC proliferation.
TNBC cells were grown in 96-well plates to 0% confluence in complete media. (A) Cells were
maintained in phenol red-free RMPI 1640 media supplemented with 2% cFBS and either NVP-AEW541
(8 µM, IGF1R inhibitor; Selleckchem) or BMS-754807 (20 µM, IGF1R/InsR inhibitor; Selleckchem),
alone or in combination; (B) Cells were exposed to media containing enzalutamide (20 µM, AR inhibitor;
Selleckchem) and proliferation was assessed after 72 h; (C) Cells were cultured in media containing
BMS-754807 and enzaluta ide for 72 h or (D) in media containing NVP-AEW754 and enzalutamide for
72 h. Thereafter, cell proliferatio was measured usi g the Celltiter 96® Aqueous Proliferation Assay
(Promega, Madison, WI, USA). # p-value < 0.05, * p-value < 0.001. SD: standard deviation (n = 3).
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2.4. BMS-754807 and NVP-AEW541 Alter AR Expression in Mesenchyma-Subtype TNBC Cells
To find if the reduction of TNBC proliferation in response to combined treatments with either
BMS-754807 or NVP-AEW541 may also affect AR expression (Figure 7), we assessed AR levels in
BT549 cells that express a robust amount of AR under baseline conditions (Figure 2, Lane 5).Int. J. Mol. Sci. 2017, 18, 2305 8 of 14 
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Figure 7. Effect of IGF1R/IR antagonists on AR expression in mesenchymal-subtype TNBC cell line
BT549. BT549 (mesenchymal-like) cultures were exposed to control (CON), BMS-754807 (BMS; 20 µM)
or NVP-AEW807 (NVP; 8 µM) for 12 or 24 h. Total protein was isolated, processed and transferred to
PVDF membranes which were probed for AR expression (1:500, Cell Signaling #5153). β-actin (1:2000,
Sigma-Adlrich #A1978) was used as a loading control. Western immunoblot representative of three
independent experiments.
Cells were exposed to both IGF1R inhibit rs for 12 or 24 h. At 12 h, the results indicate that
NVP- EW541, an antagonist that prevents auto-phosphorylation of IGF1R, reduces expression levels
of AR to a greater extent than BMS-754807, a dual IGF1R/IR inhibitor (Figure 7). Notably at 24 h both
inhibitors reduce AR expression to virtually undetectable levels by Western immunoblot.
3. Discussion
Apart from the administration of neoadjuvant and/or adjuvant cytotoxic chemotherapies,
there are currently limited therapeutic options for the majority of patients afflicted with advanced
TNBC. Emerging reports from early clinical trials suggest that anti-PD-1 or anti-PD-L1 immune
checkpoint inhibitors may have clini l benefit in very limited numbers f TNBC patients [36,37,45].
How ve , other targeted therapies that have proven effectiv for patients with ERα-positive or
HER2-overexpressing subtypes of breast cancer are not available for TNBC due to the lack of
ERα and PR expression and HER2 amplification, thus leaving most women with TNBCs without
targeted treatment options. To further investigate potential biologic targets in TNBC to improve
patient outcomes, we assessed the interplay between the IGF2 and AR signaling pathways in
TNBC proliferation.
TNBC is a heterogeneous disease that can be classified into distinct molecular subtypes by gene
expression profiling [46]. Currently, there are four TNBC subtypes, basal-like 1 (BL1), basal-like 2 (BL2),
mesenchymal-lik (M), and luminal androgen receptor expression (LAR), that de onstrate differences
in diagnosis, age, loc l and distant disease progressio , histopathology nd in the response to similar
neoadjuvant chemotherapy that may inform in the selection of optimal chemotherapeutic regimens [47].
The majority of all TNBCs are basal-like, with mesenchymal-like more common than LAR [48]. We find
that both BL and M subtypes in particular, as represented by established TNBC cell lines, respond to
IGF1R/IR and AR antagonists alone and in combination treatments. Our preclinical studies indicate
that IGF1R- and AR-targeted therapies reduce TNBC cell proliferation and induce cell death, indicating
that these receptors may serve as attractive targets for TNBC treatment going forward.
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Enzalutamide is an androgen receptor antagonist which prevents androgen receptor nuclear
translocation, coactivator recruitment and DNA binding. Although studies present mixed patient
outcomes related to high and low AR expression [29,49–53], several preclinical studies have evaluated
the therapeutic potential of AR inhibition in TNBC progression [5,54,55]. Treatment of TNBC cell
lines with enzalutamide significantly reduces TNBC proliferation, invasion and amphiregulin growth
factor secretion [32]. Although it was hypothesized that treatment with enzalutamide would only
be effective in the LAR molecular subtype of TNBC, other molecular subtypes including basal-like
and mesenchymal-like subtypes were also responsive to antiandrogen interventions [5], outcomes
that are supported by this work. Additionally, clinical trials indicate that enzalutamide, alone or in
combination, is well tolerated in women with advanced breast cancer [55–57].
Due to the molecular heterogeneity and high rate of drug resistance among TNBCs, preclinical
studies are investigating the targeting of multiple signaling pathways to stop TNBC proliferation [58].
These dual therapies have proven to be more effective in preventing TNBC proliferation compared
to single drug therapies [42,44,58]. In line with this notion, we investigated the effect of BMS-754807
and NVP-AEW541, two mono-therapies tested previously as single agents in breast cancer clinical
trials [59,60]. Our preclinical study indicates a potential benefit of BMP-754807 and NVP-AEW541
administered together and in combination with enzalutamide to stimulate TNBC cell death and reduce
TNBC proliferation. Furthermore, our experiments indicate that more profound inhibition of TNBC
cell proliferation can be achieved by the use of these drugs in combination therapies in vitro (Figure 4).
Further studies will be needed to determine whether drug combinations determined in this work are
synergistic or additive [61,62]. Additionally, the tolerability and safety of these combinations in vivo
remains to be assessed.
Importantly, the lack of clinical efficacy of IGF-targeted therapies may well be a result of the
lack of predictive biomarkers to select those patients most likely to benefit from these therapeutics.
Several preclinical studies have investigated the correlation between patient treatment outcomes
with tumors bearing a specific molecular background [23,47,63]. For example, patients with TNBC
or KRAS-mutant lung cancers may obtain optimal benefit from IGF1R inhibitor drugs [42,64,65].
Other reports suggest that genomic alterations in PI3K/AKT and IGF1R may be actionable targets
in TNBC [23]. However, the challenge in unlocking the potential for IGF-targeted therapies lies in
defining predictive biomarkers [23,47]. In prior studies, we documented increased expression of IGF2
in tumorous and in neighboring non-tumorous stromal and epithelial cells in archival breast tissue
from women with TNBC [21]. These observations implicate IGF2 in the promotion of TNBC growth via
autocrine and/or paracrine mechanisms. Independent investigators have also identified IGF2 as a key
factor in the genesis of breast tumor spheres [66]. The IGF2 receptor, IGF1R, is expressed at high levels
in cancer stem cell (CSC)-enriched populations in primary breast cancers. Moreover, IGF2-PI3K/AKT
signaling induced expression of a stemness transcription factor and IGF2 itself. Notably, treatment with
anti-IGF1/2 antibodies blocked tumorigenesis derived from the IGF1Rhigh CSC-enriched population
in a patient-derived xenograft model [66]. Similarly, AR is necessary for anchorage independence
and CSC circumvention of anoikis, processes that are inhibited by enzalutamide [67]. Our findings,
as presented here, indicate a benefit in TNBC outcomes by inhibiting IGF2 activity using targeted
therapies against IGF1R/IR and AR to prevent tumor growth and potentially metastasis.
4. Materials and Methods
4.1. Cell Culture
Cell lines were obtained from the American Type Culture Collection (ATCC) and cultured
according to ATCC recommendations. Briefly, T47D (ERα+/ERβ+) and triple negative (ERα-negative,
PR-negative, HER2-negative) cell lines HCC 1806, MDA-231, HCC 38, HCC 1937, and BT549 [21] were
cultured in RPMI 1640 media (ATCC) and with 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA),
100,000 units penicillin and 100,000 units streptomycin sulfate (Cellgro, Manassas, VA, USA). Cultures
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were maintained at 37 ◦C in a 5% CO2 atmosphere using a tissue culture incubator. For estrogen-free
conditions, cells were maintained in phenol red-free RPMI media with dextran-coated, charcoal-treated
(DCC) FBS (cFBS).
4.2. Cell Viability and Proliferation Assays
Assessment of IGF2 effects on TNBC viability was performed using 1.0 × 105 cells/well seeded in
a 6-well Transwell plate (Corning, Tewksbury, MA, USA) in complete media. After 24 h in estrogen-free
conditions, cell cultures were exposed to phenol red-free, estrogen-free RPMI media containing IGF2
(100 ng/mL; Sigma-Aldrich, St. Louis, MO, USA) for 24, 48 or 72 h. IGF2-containing medium was
replaced daily. At the indicated time points, cell numbers and cell viability were assessed using a Cell
Counter (BioRad, Hercules, CA, USA) and trypan blue dye-exclusion assays, respectively.
To assess the roles of IGF1R, IR, and AR on TNBC proliferation, 5 × 103 cells per well were plated
in 96-well plates. Cells were allowed to grow to 50–60% confluence in RPMI 1640 media containing
10% FBS. Media for test drugs were composed of phenol red-free RMPI 1640 media supplemented with
2% charcoal-dextran stripped FBS (Gemini BioProducts, West Sacramento, CA, USA) containing IGF1R
inhibitor NVP-AEW541 (8 µM, Selleckchem, Houston, TX, USA), IGF1R/InsR inhibitor BMS-754807
(20 µM, Selleckchem), or AR inhibitor enzalutamide (20 µM, Selleckchem), alone or in selected
combinations. Cell cultures were maintained in the conditioned media for 72 h. Cell proliferation
was then assessed using the Celltiter-96® Aqueous Proliferation Assay (Promega, Madison, WI, USA)
following the manufacturer’s recommended protocol.
4.3. Assays of Cell Viability and Apoptosis/Cell Death by Flow Cytometry
For flow cytometry experiments, cells were plated and grown to 80% confluence in complete
media. Cultures were then exposed to the IGF1R inhibitor NVP-AEW541 (8 µM, Selleckchem),
IGF1R/IR inhibitor BMS-754807 (20 µM, Selleckchem), or AR inhibitor enzalutamide (20 µM,
Selleckchem), in media containing phenol red-free RMPI 1640 media supplemented with 2%
charcoal-dextran-stripped FBS (Gemini BioProducts, CA, USA) for 24 or 48 h. As per the manufacturer’s
recommended protocol, cells were then removed and stained with 7-AAD and Annexin-V (Affymetrix,
Inc., San Diego, CA, USA) for viability and apoptosis assays, respectively. Cells were examined using
an LSR II Benchtop Analyzer (BD Biosciences, San Jose, CA, USA) with FlowJo Collector’s Edition
software (FloJo, LLC, Ashland, OR, USA).
4.4. Inhibition Assays
To assess the inhibitory effect of BMS-754807 and NVP-AEW541 on IGF2-stimulated signaling,
TNBC cells were grown to 75–80% confluence in complete media, then cultured for 3 h in serum-free,
and phenol red-free RPMI 1640 media. BMS-754807 (20 µM) or NVP-AEW541 (8 µM) was added to
the serum-free, and phenol red-free media for 1 h followed by the addition of IGF2 (100 ng/mL) for
20 min.
4.5. Gel Electrophoresis and Immunoblotting
To assess the expression of IGF1R, IR, and AR, TNBC cultures were maintained as described above.
Using RIPA buffer, total protein was isolated, and protein concentration was determined using the
Bradford assay. Forty micrograms of total cell protein were resolved by 4–15% SDS-PAGE, transferred
to a PVDF membrane and probed with antibodies directed against IGF1R (1:500, Cell Signaling #3027),
IR (1:500, Cell Signaling #3025), IGF2 (1:1000, AbCam ab9574), pAkt (1:1000, Cell Signaling #4060),
MAPK (1:1000, Cell Signaling #9102), pMAPK (1:1000, Cell Signaling #4370), S6 (1:2000, Cell Signaling
#2217), pS6 (1:2000, Cell Signaling #4858), and androgen receptor AR (1:500, Cell Signaling #5153).
β-actin (1:2000, Sigma-Aldrich #A1978) was used as a loading control.
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4.6. Statistical Analysis
GraphPad Prism software (Available online: www.graphpad.com) was used for statistical analysis.
Student’s t-test was used to determine significance as appropriate. p-Value < 0.05 were considered
significantly different.
5. Conclusions
New insights made from preclinical and correlative biologic studies could well lead to the
determination of predictive TNBC biomarkers that may impact clinical decision-making and provide
new avenues for mechanistic exploration leading to clinical application. Hence, our experiments on
novel dual therapies targeting IGF2 and AR signaling pathways hold promise as potential therapeutic
targets for TNBC treatment going forward. Indeed, the results of emerging studies indicate that TNBC
proliferation and survival are dependent on IGF1R/IR, and that their inhibition leads to reductions in
proliferation and increments in cell death [68]. Molecular targeting therapies that include anti-IGF1R
antibodies, anti-IGF1/IGF2 antibodies, and small molecule inhibitors that suppress IGF1R and IR
kinase activity as well as AR antagonists deserve further evaluation in the potential management
of TNBC.
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